Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
615 stopped studies mapped to Melanoma and descendants · 90% state a reason
Over the 615 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02263508 | Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma(MASTERKEY-265) | Phase 3 | terminated | Oct 13, 2014 | Amgen | not stated | Not stated |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | Phase 1 | terminated | May 8, 2015 | Amgen | not stated | Not stated |
| NCT03445533 | A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With… | Phase 3 | terminated | Feb 26, 2018 | Idera Pharmaceuticals, Inc. | Lack of Efficacy | Efficacy / futility |
| NCT01810016 | NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or… | Phase 1 | terminated | Mar 13, 2013 | Ludwig Institute for Cancer Research | Low recruitment due to change in standard of care | Enrollment / accrual |
| NCT01838200 | Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in… | Phase 1 | terminated | Apr 23, 2013 | Ludwig Institute for Cancer Research | Slow recruitment due to changes in standard of care | Enrollment / accrual |
| NCT00145158 | Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With… | Phase 1 / Phase 2 | terminated | Sep 5, 2005 | Ludwig Institute for Cancer Research | Availability of Investigational agent | Other (stated, no rule matched) |
| NCT00145145 | Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With… | Phase 1 / Phase 2 | terminated | Sep 5, 2005 | Ludwig Institute for Cancer Research | Poor Accrual | Enrollment / accrual |
| NCT02601378 | A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. | Phase 1 | terminated | Nov 10, 2015 | Novartis Pharmaceuticals | The combination part of the study was terminated early due to business reasons | Sponsor / business decision |
| NCT03301636 | A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With…(NLG2107) | Phase 2 | terminated | Oct 4, 2017 | NewLink Genetics Corporation | Sponsor termination, not related to efficacy, safety or feasibility. | Safety / toxicity |
| NCT00507325 | Sample Collection From Melanoma Patients | — | terminated | Jul 26, 2007 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT03526185 | A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes | Early Phase 1 | terminated | May 16, 2018 | Yale University | lack of funds | Funding |
| NCT01744171 | Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma | Phase 1 | terminated | Dec 6, 2012 | Roswell Park Cancer Institute | Study was Suspended since 2018; PI decided to terminate. | Other (stated, no rule matched) |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT03754140 | Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases(INTRANS) | Phase 2 | withdrawn | Nov 27, 2018 | Melanoma Institute Australia | Unable to identify eligible patients within planned timeframe | Other (stated, no rule matched) |
| NCT03259425 | Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in… | Phase 2 | terminated | Aug 23, 2017 | University of Utah | DSMC Recommendation | Other (stated, no rule matched) |
| NCT03332589 | E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System… | Phase 1 | terminated | Nov 6, 2017 | Spirita Oncology, LLC | Single center study: Principal Investigator left institution. | Investigator |
| NCT02854488 | Yervoy Pregnancy Surveillance Study | — | withdrawn | Aug 3, 2016 | Bristol-Myers Squibb | During the study period, no participants were enrolled in the study despite extensive recruitment… | Enrollment / accrual |
| NCT01940809 | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients… | Phase 1 | terminated | Sep 12, 2013 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | Phase 2 | terminated | Jun 1, 2015 | TC Biopharm | not stated | Not stated |
| NCT01650350 | Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal… | Phase 2 | terminated | Jul 26, 2012 | Brown University | Study stopped 10/24/13 secondary to lack of patients/slow enrollment | Enrollment / accrual |
| NCT01930968 | Definity for Ultrasound of Intraocular Tumors | — | withdrawn | Aug 29, 2013 | Emory University | Study did not receive funding to move forward | Funding |
| NCT01918930 | Tissue Procurement Substudy for Participants in Study CP-MGA271-01 | Phase 1 | terminated | Aug 8, 2013 | MacroGenics | Unable to accrue as planned for optional biopsies | Enrollment / accrual |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT02054104 | Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral… | Phase 1 / Phase 2 | terminated | Feb 4, 2014 | National Cancer Institute (NCI) | Vaccine production halted in 2015, thus study is terminated. | Other (stated, no rule matched) |
| NCT02288897 | PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced… | Phase 3 | terminated | Nov 11, 2014 | Provectus Biopharmaceuticals, Inc. | Inadequate rate of enrollment | Enrollment / accrual |
| NCT02818023 | Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma | Phase 1 | terminated | Jun 29, 2016 | Yana Najjar | Accrual to trial stopped due to high toxicity even at lowest dose of combination treatment.… | Safety / toxicity |
| NCT04648826 | Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune… | Phase 1 / Phase 2 | withdrawn | Dec 2, 2020 | National Cancer Institute (NCI) | Due to notification from EMD Serono, for Bintrafusp alfa (M7824) regarding an observed increase in… | Other (stated, no rule matched) |
| NCT00758797 | A Novel Treatment for Metastatic Melanoma | Phase 1 | terminated | Sep 25, 2008 | Northwestern University | Study was not renewed during annual Northwestern Cancer Center review. | Other (stated, no rule matched) |
| NCT04223648 | Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and… | Early Phase 1 | withdrawn | Jan 10, 2020 | Yale University | Funding | Funding |
| NCT03407040 | Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells… | — | terminated | Jan 23, 2018 | National Cancer Institute (NCI) | Investigator left NIH | Investigator |
| NCT04995094 | Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma | Phase 2 | withdrawn | Aug 6, 2021 | HiberCell, Inc. | Enrollment challenges, study not feasible | Enrollment / accrual |
| NCT02009384 | Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With… | Phase 2 | terminated | Dec 12, 2013 | University of Louisville | low enrollment r/t requirement of prior treatment with denileukin diftitox | Enrollment / accrual |
| NCT02355574 | 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile…(INTEGRATE) | — | terminated | Feb 4, 2015 | Castle Biosciences Incorporated | Study endpoints completed with lower than anticipated enrollment. Last patient enrolled completed… | Enrollment / accrual |
| NCT02355587 | Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous…(EXPAND) | — | terminated | Feb 4, 2015 | Castle Biosciences Incorporated | Study goals were met with smaller that expected study cohort. Last patient completed the study June… | Other (stated, no rule matched) |
| NCT00615160 | PTK/ZK in Disseminated Malignant Melanoma | Phase 1 / Phase 2 | terminated | Feb 14, 2008 | Michael Weichenthal | Substance was withdrawn from further development. | Other (stated, no rule matched) |
| NCT02375984 | A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in…(TIL) | Phase 2 | terminated | Mar 3, 2015 | Saint John's Cancer Institute | PI changed institutions | Other (stated, no rule matched) |
| NCT02974803 | Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive… | Phase 2 | terminated | Nov 28, 2016 | Canadian Cancer Trials Group | Very slow accrual | Enrollment / accrual |
| NCT02521870 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in… | Phase 1 / Phase 2 | terminated | Aug 13, 2015 | Dynavax Technologies Corporation | A strategic restructuring including the planned conclusion of clinical oncology development… | Sponsor / business decision |
| NCT04955262 | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr… | Phase 1 | withdrawn | Jul 8, 2021 | Nektar Therapeutics | Did not initiate due to business reasons. IND is inactive. | Sponsor / business decision |
| NCT02650492 | Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma | N/A | terminated | Jan 8, 2016 | Clinical Laserthermia Systems AB | Study was stopped in agreement with investigator due to slow patient recruitment. | Investigator |
| NCT03394937 | Safety of Intranodal ECI-006 in Melanoma Patients | Phase 1 | terminated | Jan 9, 2018 | eTheRNA immunotherapies | Expiry of study medication | Other (stated, no rule matched) |
| NCT04060407 | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)(CINDI) | Phase 1 / Phase 2 | withdrawn | Aug 19, 2019 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business Reasons | Sponsor / business decision |
| NCT02097732 | Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic… | Phase 2 | terminated | Mar 27, 2014 | University of Michigan Rogel Cancer Center | Study halted prematurely due to a change in the standard of care treatment | Other (stated, no rule matched) |
| NCT04473027 | BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs(BLOOD) | — | terminated | Jul 16, 2020 | University Hospital, Ghent | Low patient inclusion | Other (stated, no rule matched) |
| NCT03224208 | Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients(VECODUE) | Phase 2 | terminated | Jul 21, 2017 | Fondazione Melanoma Onlus | low enrolment rate | Enrollment / accrual |
| NCT03724968 | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II… | Phase 2 | terminated | Oct 30, 2018 | Elizabeth Davis | Loss of funding | Funding |
| NCT04042506 | SBRT as a Vaccination for Metastatic Melanoma | Phase 2 | withdrawn | Aug 2, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Unable to enroll patients in this study | Enrollment / accrual |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated…(Pelican) | Phase 1 | withdrawn | Dec 12, 2018 | Turnstone Biologics, Corp. | insufficient suitable drug supply | Drug supply |
| NCT03425461 | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating… | Phase 1 | terminated | Feb 7, 2018 | Jonsson Comprehensive Cancer Center | funding | Funding |
| NCT04495010 | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant…(CheckMate 7UA) | Phase 2 | withdrawn | Jul 31, 2020 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 14, 2022source: clinicaltrials